<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.03">
 <iati-activity default-currency="USD" hierarchy="1" humanitarian="0" iati-activities:version="2.03" xml:lang="EN" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities">
  <iati-identifier>SE-0-SE-29-2021-05727-282-12262</iati-identifier>
  <reporting-org ref="SE-0" secondary-reporter="0" type="10">
   <narrative xml:lang="EN">Sweden</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="EN">Tackling the imminent risk of P. falciparum resistance to ACT in East-Africa: are two sequential ACTs better than triple ACT?</narrative>
   <narrative xml:lang="SV">&#xC5;tg&#xE4;rder f&#xF6;r att hantera den &#xF6;verh&#xE4;ngande risken f&#xF6;r P. falciparum resistens mot ACT i &#xD6;st-Afrika - &#xE4;r sekventiell behandling med tv&#xE5; ACT b&#xE4;</narrative>
  </title>
  <description type="1">
   <narrative xml:lang="EN">Global malaria case management is presently threatened by P. falciparum resistance to artemisinin-based combination therapy (ACT). While awaiting access to new antimalarial compounds, to replace ACT, it is critical to evaluate new strategies to optimize the use of the presently available ACTs.The main project aim and objective is to study if treatment of uncomplicated childhood Falciparum malaria in Tanzania with two sequential ACTs, i.e. artemether-lumefantrine (AL) for 3 days followed by artesunate-amodiaquine for 3 days (=6 days of ACT), is superior to triple ACT, AL+amodiaquine for 3 days, to ensure parasitological cure/protection against recurrent parasitemia and thereby to prevent ACT resistance. The two interventions will be compared with standard 3-day AL treatment in a randomized trial, with 140 patients/arm. Study outcomes include crude and PCR adjusted cure rates by day 28, 42 and 56, microscopy and PCR determined parasite clearance, post-treatment prophylaxis, time to recurrent parasitemia, selection of ACT resistance markers among recurrent infections, pharmacokinetic profiles, and safety. The study will be conducted in Bagamoyo District, Tanzania, in close collaboration with partners from Muhimbili University. Project duration is 2 years. The project will contribute with critically needed data on new strategies to prolong the useful therapeutic lifespan of ACT as lifesaving drugs for P. falciparum malaria in an era of imminent ACT resistance risk in East Africa.</narrative>
   <narrative xml:lang="SV">Plasmodium falciparum malaria &#xE4;r en av v&#xE5;r tids viktigaste sjukdomar ur ett globalt perspektiv.Artemisininbaserad kombinationsterapi (ACT) &#xE4;r den mest effektiva behandlingen som idag finns tillg&#xE4;nglig mot malaria. Utveckling av resistens mot dessa l&#xE4;kemedel skulle f&#xE5; allvarliga konsekvenser f&#xF6;r global malariakontroll, dels f&#xF6;r de minsta barnens h&#xE4;lsa, d&#xE5; det flesta d&#xF6;dsfall i malaria drabbar barn, dels pga att inga riktigt bra behandlingsalternativ till ACT finns tillg&#xE4;ngliga idag.Vi har nyligen noterat tecken hos malariaparasiten Plasmodium falciparum i Tanzania att den b&#xF6;rjat utveckla viss motst&#xE5;ndskraft mot ACT. I till&#xE4;gg finns nu data som bekr&#xE4;ftar att malariaparasiten i Sydostasien utvecklat resistens mot ACT med behandlingsmisslyckanden som f&#xF6;ljd.V&#xE5;r bed&#xF6;mning &#xE4;r d&#xE4;rf&#xF6;r att det kan f&#xF6;religga risk f&#xF6;r ACT resistens &#xE4;ven i Tanzania. I v&#xE4;ntan p&#xE5; att nya l&#xE4;kemedel finns tillg&#xE4;ngliga &#xE4;r det av st&#xF6;rsta vikt att finna nya strategier syftande till att f&#xF6;rl&#xE4;nga den terapeutiska livsl&#xE4;ngden av ACT.I denna studie &#xE4;mnar vi studera betydelsen av tv&#xE5; interventioner: dels att kombinera standardbehandling f&#xF6;r okomplicerad malariasjukdom i Tanzania (artemether-lumefantrine) med amodiakin under 3 dagar, s&#xE5; kallad trippel-ACT behandling, dels genom sekventiell behandling med tv&#xE5; olika ACT:er, artemether-lumefantrien under 3 dagar f&#xF6;ljt av artesunate-amodiakin under 3 dagar, dvs en totalbehandling p&#xE5; 6 dagar.Behandlingseffekten och s&#xE4;kerhetsprofilen av de tv&#xE5; nya l&#xE4;kemedelskombinationerna kommer att studeras noggrant och j&#xE4;mf&#xF6;ras med r&#xE5;dande standardbehandling, dvs 3 dagars behandling med artemether-lumefantrine.Studien kommer att genomf&#xF6;ras i Bagamoyo distriktet i Tanzania, d&#xE4;r v&#xE5;rt forskningsteam har stor erfarenhet av att genomf&#xF6;ra malariaforskningsstudier i n&#xE4;ra samarbete med kollegor fr&#xE5;n Muhimbili universitetet i Dar es Salaam.Vi bed&#xF6;mer att resultaten fr&#xE5;n denna studie kan ha stor betydelse att utv&#xE4;rdera nya strategier med syfte att f&#xF6;rl&#xE4;nga den terapeutiska livsl&#xE4;ngden av artemisinin-baserad kombinationsbehandling i en tid av &#xF6;verh&#xE4;ngande Plasmodium falciparum resistens i &#xD6;stafrika.</narrative>
  </description>
  <participating-org ref="SE-0" role="1" type="10">
   <narrative xml:lang="EN">Sweden</narrative>
  </participating-org>
  <participating-org ref="SE-29" role="3" type="10">
   <narrative xml:lang="EN">The Swedish Research Council</narrative>
  </participating-org>
  <participating-org ref="51000" role="4" type="80">
   <narrative xml:lang="EN">University, college or other teaching institution, research institute or think-tank</narrative>
  </participating-org>
  <activity-status code="2"></activity-status>
  <activity-date iso-date="2022-01-01" type="1"></activity-date>
  <activity-date iso-date="2023-12-31" type="3"></activity-date>
  <contact-info>
   <organisation>
    <narrative xml:lang="EN">The Swedish Research Council</narrative>
   </organisation>
   <telephone>+46 8 546 44 000</telephone>
   <email>vetenskapsradet@vr.se</email>
   <website>www.vr.se</website>
   <mailing-address>
    <narrative xml:lang="EN">Box 1035, 101 38 Stockholm, Sweden</narrative>
   </mailing-address>
  </contact-info>
  <recipient-country code="TZ" percentage="100">
   <narrative xml:lang="EN">Tanzania, United Republic of</narrative>
  </recipient-country>
  <sector code="122" percentage="100" vocabulary="2">
   <narrative xml:lang="EN">Basic Health</narrative>
  </sector>
  <sector code="12262" percentage="100" vocabulary="1">
   <narrative xml:lang="EN">Malaria control</narrative>
  </sector>
  <policy-marker code="5" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Convention on Biological Diversity</narrative>
  </policy-marker>
  <policy-marker code="8" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Convention to Combat Desertification</narrative>
  </policy-marker>
  <policy-marker code="7" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Framework Convention on Climate Change - Adaptation</narrative>
  </policy-marker>
  <policy-marker code="6" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Framework Convention on Climate Change - Mitigation</narrative>
  </policy-marker>
  <policy-marker code="2" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid to Environment</narrative>
  </policy-marker>
  <policy-marker code="11" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Disability</narrative>
  </policy-marker>
  <policy-marker code="10" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Disaster Risk Reduction(DRR)</narrative>
  </policy-marker>
  <policy-marker code="1" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Gender Equality</narrative>
  </policy-marker>
  <policy-marker code="3" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Participatory Development/Good Governance</narrative>
  </policy-marker>
  <policy-marker code="9" significance="2" vocabulary="1">
   <narrative xml:lang="EN">Reproductive, Maternal, Newborn and Child Health (RMNCH)</narrative>
  </policy-marker>
  <policy-marker code="4" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Trade Development</narrative>
  </policy-marker>
  <collaboration-type code="1"></collaboration-type>
  <default-flow-type code="10"></default-flow-type>
  <default-finance-type code="110"></default-finance-type>
  <default-aid-type code="D02" vocabulary="1"></default-aid-type>
  <default-tied-status code="4"></default-tied-status>
  <budget>
   <period-start iso-date="2022-01-01"></period-start>
   <period-end iso-date="2022-12-28"></period-end>
   <value currency="USD" value-date="2022-01-01">186547.5871235528</value>
  </budget>
  <budget>
   <period-start iso-date="2023-01-01"></period-start>
   <period-end iso-date="2023-12-28"></period-end>
   <value currency="USD" value-date="2023-01-01">163229.1387331087</value>
  </budget>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2021-11-25"></transaction-date>
   <value currency="USD" value-date="2021-11-25">349776.7258566615</value>
  </transaction>
  <crs-add>
   <other-flags code="1" significance="1"></other-flags>
  </crs-add>
  <sida:contribution xmlns:sida="http://sida.se/ns/contribution#"></sida:contribution>
 </iati-activity>
</iati-activities>
